Quick Answer
New 2025-2026 clinical trials show semaglutide (Ozempic) significantly improves menstrual regularity, reduces androgens, and may restore ovulation in women with PCOS and obesity. It is not yet officially approved for PCOS but is increasingly prescribed off-label by specialists in India.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
Polycystic ovary syndrome — PCOS — is the most common hormonal disorder in women of reproductive age in India. Estimates suggest that one in five Indian women has PCOS, making it an enormous public health issue that causes irregular periods, excess facial and body hair, acne, difficulty conceiving, and long-term metabolic complications including type 2 diabetes and heart disease. For years, treatment options have been limited: metformin to improve insulin sensitivity, birth control pills to regulate cycles, and lifestyle changes that are difficult to sustain. Now, a growing body of clinical trial evidence from 2025 and 2026 is pointing to a new option — semaglutide, the active ingredient in Ozempic and Wegovy — as a drug that may address PCOS at its metabolic roots in a way that older treatments cannot.
What the New Clinical Trials Found
In 2025, a randomized controlled trial published in the journal Metabolism and Target Organ Damage examined what happened when overweight and obese women with PCOS were given either semaglutide alone, metformin alone, or semaglutide combined with metformin. The results were striking. Women in the semaglutide group showed significant improvements in menstrual cyclicity — meaning their periods became more regular — along with meaningful reductions in testosterone and other androgen hormones that cause excess hair growth and acne. Women on the combination of semaglutide and metformin showed the greatest overall improvements across weight, blood sugar, hormone levels, and menstrual regularity.
A second prospective study published in the journal Gynecological Endocrinology in 2025 followed obese women with PCOS who were trying to conceive. Participants on semaglutide lost significant body weight and showed improvements in ovulation rates — a critical outcome for women who have irregular or absent ovulation due to PCOS. Hormonal profiles normalised, with lower levels of LH (luteinising hormone) and androgens, and higher levels of SHBG (sex hormone-binding globulin), all of which are markers of improved reproductive function. A 2026 review published in the Journal of Clinical Medicine examined all available evidence and concluded that semaglutide represents an important tool for treating irregular periods and chronic anovulation in women with PCOS.
Why Does Semaglutide Help with PCOS?
PCOS is fundamentally a condition of insulin resistance in most women who have it. When cells resist insulin, the body produces more of it to compensate, and high insulin levels directly stimulate the ovaries to produce excess testosterone. This cascade — insulin resistance driving androgen excess driving ovulatory dysfunction — is the core engine of PCOS. Most women with PCOS who are overweight have significant insulin resistance, and even women with PCOS who are a normal weight frequently have underlying metabolic dysfunction.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
Semaglutide works through multiple pathways that directly address this problem. It improves insulin sensitivity, reduces overall caloric intake, and produces significant weight loss — in clinical trials of women with PCOS, participants lost between 10% and 15% of their body weight. As adipose (fat) tissue decreases, estrogen production from fat cells falls, insulin resistance improves, androgen levels drop, and the hypothalamic-pituitary-ovarian axis that governs menstrual cycles begins to normalise. This is why women who were not ovulating regularly find that ovulatory cycles return as their body weight decreases on semaglutide — a benefit that metformin alone rarely achieves to the same degree.
What This Means for Indian Women with PCOS
India has a particular dimension to this story. Indian women with PCOS tend to have more severe insulin resistance at lower body weights than women in Western populations. Research has consistently shown that Indian women develop metabolic complications of PCOS — including pre-diabetes and type 2 diabetes — at BMIs that would not be considered high-risk in European populations. This means that the metabolic benefits of semaglutide could be especially significant for Indian women with PCOS, even those who are not severely obese by standard criteria.
For Indian women who have been struggling with irregular periods, excess hair growth, persistent acne, and difficulty conceiving, semaglutide offers something that existing treatments have not: a single medication that addresses weight, insulin resistance, androgen levels, and menstrual regularity simultaneously. Metformin reduces insulin resistance but produces modest weight loss. Birth control pills regularise cycles but do not address the underlying metabolic dysfunction and are not an option for women trying to conceive. Inositol supplements have weak evidence. Semaglutide, by contrast, is now supported by multiple randomised trials showing improvements across all the key parameters of PCOS.
An Important Caution
Semaglutide is not yet officially approved by the Indian drug regulator CDSCO for the treatment of PCOS. In India, it is approved for type 2 diabetes (as Ozempic) and for weight management in obesity (as Wegovy). Prescribing it for PCOS is currently off-label, which means doctors can prescribe it at their clinical discretion but it is not a standard first-line PCOS treatment. Women with PCOS who are also overweight or obese, or who have prediabetes or insulin resistance, are most likely to be considered suitable candidates by a specialist. Women with PCOS who are trying to conceive should work with a reproductive endocrinologist who can also manage ovulation timing and other aspects of fertility treatment alongside semaglutide therapy.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
Semaglutide is also contraindicated in pregnancy and must be stopped at least two months before attempting to conceive. Women who are considering using semaglutide to improve their metabolic profile and ovulatory function before a planned conception — a strategy supported by the clinical evidence — should discuss the timing carefully with their specialist.
Generic semaglutide is now available in India from as low as Rs 1,290 per month following the March 2026 patent expiry, making this a more accessible option than it was previously. A GLP-1 specialist can assess whether you are a candidate, guide you through the dose escalation schedule, and monitor your hormonal and metabolic response over time.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. Metabolism and Target Organ Damage — Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with PCOS — https://www.oaepublish.com/articles/mtod.2025.210 2. PMC/NIH — Effects of combined metformin and semaglutide therapy on reproductive outcomes in PCOS — https://pmc.ncbi.nlm.nih.gov/articles/PMC12297736/ 3. Journal of Clinical Medicine — Evidence that semaglutide represents an important tool for treatment of irregular menses in PCOS — https://doi.org/10.3390/jcm15135165
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.